RUA Life Sciences has released a trading update for the 12-months to March 2022, noting revenues are expected to be £1.6m, up 6% YoY (Cenkos est £1.8m), loss before tax of £2.4m (Cenkos est £2.8m) and year-end cash of £3.0m (Cenkos est £1.8m). The company has provided an update on its four business divisions, with a discussion on the progress of the vascular graft programme which was delayed towards the end of 2021. RUA are targeting vascular graft approval in late 2024 with a market launch in 2 ....
